Neoadjuvante Therapie des Pankreaskarzinoms – neue Chancen

Das duktale Adenokarzinom des Pankreas (PDAC) ist nach wie vor eine Tumorerkrankung mit ungünstiger Prognose, wofür die 5-Jahres-Gesamtüberlebensrate von weniger als 10% stellvertretend steht [1].
Wie aktuell die Evidenz für die neoadjuvante/perioperative Therapie in unterschiedlichen Therapiesituationen aussieht, wird im Folgenden dargestellt.

Schlüsselwörter

neoadjuvante Therapie - Pankreaskarzinom - Resektabilitätskriterien

• Literatur

• 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
• 2 Haeno H, Gonen M, Davis MB. et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012; 148 (01/02) 362-375
• 3 WHO. Fact sheet pancreatic cancer. 2020 Accessed August 19, 2023 at: https://gco.iarc.fr/today/data/factsheets/cancers/13-Pancreas-fact-sheet.pdf
• 4 Robert-Koch-Institut. Zentrum für Krebsregisterdaten (ZfKD). Accessed August 19, 2023 at: www.krebsdaten.de
• 5 Gillen S, Schuster T, Meyer Zum Buschenfelde C. et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7 (04) e1000267
• 6 Seufferlein T, Mayerle J, Bock S. et al. S3-guideline exocrine pancreatic cancer. Z Gastroenterol 2022; 60 (06) 991-1037
• 7 Isaji S, Mizuno S, Windsor JA. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018; 18 (01) 2-11
• 8 Hartwig W, Strobel O, Hinz U. et al. CA19–9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 2013; 20 (07) 2188-2196
• 9 Bergquist JR, Puig CA, Shubert CR. et al. Carbohydrate Antigen 19–9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. J Am Coll Surg 2016; 223 (01) 52-65
• 10 Conroy T, Castan F, Lopez A. et al. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. JAMA Oncol 2022; 8 (11) 1571-1578
• 11 Oettle H, Neuhaus P, Hochhaus A. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA: Journal of the American Medical Association 2013; 310 (14) 1473-1481
• 12 Neoptolemos JP, Palmer DH, Ghaneh P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017; 389: 1011-1024
• 13 Al-Batran SE, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019; 393: 1948-1957
• 14 Sauer R, Liersch T, Merkel S. et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30 (16) 1926-1933
• 15 Thomas Jens E, Waldemar U, Marko K. et al. Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Updated final results of the randomized phase II AIO-NEONAX trial. Journal of Clinical Oncology 2022; 40 (Suppl. 16) 4133-4133
• 16 Sohal DPS, Duong M, Ahmad SA. et al. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2021; 7 (03) 421-427
• 17 Ghaneh P, Palmer D, Cicconi S. et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2023; 8 (02) 157-168
• 18 Fietkau R, Ghadimi M, Grützmann R. et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial. Journal of Clinical Oncology 2022; 40 (Suppl. 16) 4008-4008
• 19 Versteijne E, van Dam JL, Suker M. et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol 2022; 40 (11) 1220-1230
• 20 Seufferlein T, Uhl W, Kornmann M. et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol 2023; 34 (01) 91-100
• 21 Satoi S, Unno M, Motoi F. et al. The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05). Journal of Clinical Oncology 2019; 37 (Suppl. 15) 4126-4126
• 22 Seufferlein T, Uhl W, Algül H. et al. LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Results of the NEONAX trial, a randomized phase II AIO study. Annals of Oncology 2021; 32: S1333
• 23 Sohal D, Duong MT, Ahmad SA. et al. SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). Journal of Clinical Oncology 2020; 38 (Suppl. 15) 4504-4504
• 24 Versteijne E, van Dam JL, Suker M. et al. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol 2022; 40 (11) 1220-1230
• 25 Bratlie SO, Biörserud C, Björnsson B. et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1). Journal of Clinical Oncology 2023; 41 (Suppl. 17) LBA4005-LBA4005
• 26 Janssen QP, van Dam JL, Bonsing BA. et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 2021; 21 (01) 300
• 27 Suker M, Beumer BR, Sadot E. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016; 17 (06) 801-810
• 28 Philip PA, Lacy J, Portales F. et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 2020; 5 (03) 285-294
• 29 Kunzmann V, Siveke JT, Algul H. et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (02) 128-138
• 30 Hammel P, Huguet F, van Laethem JL. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 2016; 315 (17) 1844-1853
• 31 Reyngold M, O’Reilly EM, Varghese AM. et al. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. JAMA Oncol 2021; 7 (05) 735-738
• 32 Ferrone CR, Marchegiani G, Hong TS. et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015; 261 (01) 12-17